Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Brief Note: Response to Benatar.

Kelland LA.

J Interpers Violence. 2015 Nov;30(19):3424-8. doi: 10.1177/0886260514563838. Epub 2015 Jan 14.

PMID:
25592400
2.

The harm of male-on-female rape: a response to David Benatar.

Kelland L.

J Interpers Violence. 2014 Oct;29(15):2775-91. doi: 10.1177/0886260514526061. Epub 2014 Apr 10.

PMID:
24729129
3.

Luminescent 'On-Off' CdSe/ZnS quantum dot chemodosimeter for hydroxide based on photoinduced electron transfer from a carboxylate moiety.

Gauci LA, Kelland LG, Magri DC.

J Fluoresc. 2013 Jul;23(4):793-8. doi: 10.1007/s10895-013-1212-z. Epub 2013 Mar 16.

PMID:
23504217
4.

Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.

Wilson SC, Atrash B, Barlow C, Eccles S, Fischer PM, Hayes A, Kelland L, Jackson W, Jarman M, Mirza A, Moreno J, Nutley BP, Raynaud FI, Sheldrake P, Walton M, Westwood R, Whittaker S, Workman P, McDonald E.

Bioorg Med Chem. 2011 Nov 15;19(22):6949-65. doi: 10.1016/j.bmc.2011.08.051. Epub 2011 Aug 31.

PMID:
21982796
5.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

6.

Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells.

Evans IM, Bagherzadeh A, Charles M, Raynham T, Ireson C, Boakes A, Kelland L, Zachary IC.

Biochem J. 2010 Aug 1;429(3):565-72. doi: 10.1042/BJ20100578.

7.

A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S.

Mol Cancer Ther. 2010 May;9(5):1136-46. doi: 10.1158/1535-7163.MCT-09-1145. Epub 2010 May 4. Erratum in: Mol Cancer Ther. 2010 Jul;9(7):2153. Bagherazadeh, Azadeh [corrected to Bagherzadeh, Azadeh].

8.

G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.

Gunaratnam M, Green C, Moreira JB, Moorhouse AD, Kelland LR, Moses JE, Neidle S.

Biochem Pharmacol. 2009 Jul 15;78(2):115-22.

PMID:
19475728
9.

DNA-interactive agents.

Kelland L.

IDrugs. 1998 Aug;1(4):397-8.

PMID:
18465568
10.

Signal transduction pathways.

Kelland L.

IDrugs. 1998 Aug;1(4):394-6.

PMID:
18465567
12.

Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.

Hegmans A, Kasparkova J, Vrana O, Kelland LR, Brabec V, Farrell NP.

J Med Chem. 2008 Apr 10;51(7):2254-60. doi: 10.1021/jm070813z. Epub 2008 Mar 14.

13.
14.

The resurgence of platinum-based cancer chemotherapy.

Kelland L.

Nat Rev Cancer. 2007 Aug;7(8):573-84. Epub 2007 Jul 12. Review.

PMID:
17625587
15.

Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.

Kelland L.

Expert Opin Investig Drugs. 2007 Jul;16(7):1009-21. Review.

PMID:
17594186
16.

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P.

Cancer Res. 2007 Jun 15;67(12):5840-50.

17.
18.

Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.

Kelland L.

Curr Opin Mol Ther. 2007 Feb;9(1):86-91.

PMID:
17330406
19.

Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents.

Martins C, Gunaratnam M, Stuart J, Makwana V, Greciano O, Reszka AP, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2293-8. Epub 2007 Jan 25.

PMID:
17276687
20.

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Zhao L, Marshall ES, Kelland LR, Baguley BC.

Invest New Drugs. 2007 Jun;25(3):271-6. Epub 2007 Jan 3.

PMID:
17203401
21.

Discovery and development of anticancer aptamers.

Ireson CR, Kelland LR.

Mol Cancer Ther. 2006 Dec;5(12):2957-62. Review.

22.

Discontinued drugs in 2005: oncology drugs.

Kelland L.

Expert Opin Investig Drugs. 2006 Nov;15(11):1309-18.

PMID:
17040193
23.

Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol.

Nicoll K, Robertson J, Lant N, Kelland LR, Rogers PM, Robins DJ.

Oncol Res. 2006;16(2):97-106.

PMID:
16898270
25.

EuroTIDES 2005--Sixth Annual IBC Conference.

Kelland L.

IDrugs. 2006 Feb;9(2):101-4. No abstract available.

PMID:
16523397
26.

Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

Harris AL, Yang X, Hegmans A, Povirk L, Ryan JJ, Kelland L, Farrell NP.

Inorg Chem. 2005 Dec 26;44(26):9598-600.

PMID:
16363817
27.

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI.

Br J Cancer. 2005 Oct 31;93(9):1011-8.

28.

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.

Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32.

29.
30.

Small molecule anticancer drugs.

Kelland LR.

IDrugs. 1999 Jun;2(6):550-2.

PMID:
16127615
31.
32.

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P.

Clin Cancer Res. 2005 Jul 1;11(13):4875-87.

33.

Emerging drugs for ovarian cancer.

Kelland LR.

Expert Opin Emerg Drugs. 2005 May;10(2):413-24. Review.

PMID:
15934876
34.

Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.

McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP.

Clin Cancer Res. 2005 May 15;11(10):3705-13.

36.
37.

Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding.

Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5845-9.

PMID:
15501053
38.

A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.

Incles CM, Schultes CM, Kempski H, Koehler H, Kelland LR, Neidle S.

Mol Cancer Ther. 2004 Oct;3(10):1201-6.

39.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.

Cancer Res. 2004 Sep 15;64(18):6693-9.

40.

Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.

Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.

Anticancer Res. 2004 Mar-Apr;24(2B):907-19.

41.
42.

Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH.

J Med Chem. 2004 Mar 25;47(7):1856-9.

PMID:
15027879
43.

Variation in RNA expression and genomic DNA content acquired during cell culture.

Hiorns LR, Bradshaw TD, Skelton LA, Yu Q, Kelland LR, Leyland-Jones B.

Br J Cancer. 2004 Jan 26;90(2):476-82.

44.

Bioreductive prodrugs for cancer therapy.

Seddon B, Kelland LR, Workman P.

Methods Mol Med. 2004;90:515-42. Review. No abstract available.

PMID:
14657582
46.

Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.

Harrison RJ, Cuesta J, Chessari G, Read MA, Basra SK, Reszka AP, Morrell J, Gowan SM, Incles CM, Tanious FA, Wilson WD, Kelland LR, Neidle S.

J Med Chem. 2003 Oct 9;46(21):4463-76.

PMID:
14521409
47.

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A.

J Clin Oncol. 2003 Jul 1;21(13):2492-9.

PMID:
12829668
48.

Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.

Pearson VC, Ferguson J, Rogers PM, Kelland LR, Robins DJ.

Oncol Res. 2003;13(11):503-12.

PMID:
12812364
49.

Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.

Urbaniak MD, Frost LM, Bingham JP, Kelland LR, Hartley JA, Woolfson DN, Caddick S.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):2025-7.

PMID:
12781188
50.

Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics.

McSheehy PM, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR.

Eur J Cancer. 2003 Mar;39(4):532-40.

PMID:
12751386

Supplemental Content

Loading ...
Support Center